Primary Progressive Multiple Sclerosis (PPMS) is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Primary Progressive Multiple Sclerosis (PPMS) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Primary Progressive Multiple Sclerosis (PPMS) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Primary Progressive Multiple Sclerosis (PPMS) overview
Primary progressive multiple sclerosis (PPMS) is a rare and disabling form of MS that affects the brain, spinal cord, and optic nerves. Unlike other types of MS, PPMS does not have relapses or remissions, but causes steady worsening of neurological functions from the onset. PPMS affects about 10% of people with MS, and it occurs equally in men and women. The average age of diagnosis is around 40 years. The symptoms of PPMS vary from person to person, but they often include problems with walking, balance, vision, muscle weakness, pain, fatigue, cognitive impairment, and bladder and bowel dysfunction. There is no cure for PPMS, but treatments can help manage symptoms and improve quality of life. PPMS is diagnosed based on clinical history, physical examination, MRI scans, spinal fluid analysis, and other tests.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Primary Progressive Multiple Sclerosis (PPMS), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
